hCG — 10,000iu
279.99€
PT-141 — 10mg
The melanocortin peptide studied for central nervous system pathways of sexual function.
144.99€
Ex Tax 144.99€
- In Stock
- Evidence tier: Established
- Format: Lyophilized
- Purity: 99.3%
- Vial size: 10mg
For laboratory research use only. Not for human or veterinary use.
About PT-141
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its effects on sexual function through central nervous system pathways rather than vascular mechanisms. Unlike PDE5 inhibitors that act peripherally, PT-141 works through melanocortin-4 receptors in the brain. It is one of the most studied peptides in sexual health research, with extensive published clinical data.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its effects on sexual function through central nervous system pathways rather than vascular mechanisms. Unlike PDE5 inhibitors that act peripherally, PT-141 works through melanocortin-4 receptors in the brain. It is one of the most studied peptides in sexual health research, with extensive published clinical data.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It activates MC3R and MC4R receptors in the hypothalamus, triggering downstream neural signaling cascades that modulate sexual arousal and desire through central nervous system pathways rather than peripheral vasodilation. The MC4R activation increases dopaminergic and oxytocinergic signaling in brain regions associated with sexual motivation. Notably, it works independently of nitric oxide/PDE5 pathways (unlike sildenafil/tadalafil).
Mechanism clarity: Well-characterized
Tags
Key takeaways
-
Research score 9/10
186+ published studies in the dataset
-
Evidence tier: Established
Established — FDA-approved as Vyleesi for female HSDD. Multiple Phase 3 trials. Well-characterized mechanism. Clinical use in both genders supported by data.
-
Human data
Multiple Phase III RCTs; FDA-approved as Vyleesi for HSDD in premenopausal women
Storage and handling
Lyophilised powder: Room temperature or refrigerated
After reconstitution: Refrigerate; use within 30 days
Safety and limitations
Studied for: Male erectile dysfunction, Female hypoactive sexual desire disorder, Libido enhancement, Sexual performance optimization
Reported onset: 45 minutes to 2 hours for onset; effects may last 6-12 hours
Reported duration: As-needed basis — 0.5-2mg SC, 1-4 hours before activity. Max 8 doses/month (FDA labeling). NOT a daily cycle peptide.
Community reports: Users split: some report life-changing libido enhancement, others report severe nausea that outweighs benefits. Key tip: 'Start low (0.5mg) to assess nausea tolerance before going higher.' Men generally more positive. Brain-based mechanism is a major selling point for PDE5 inhibitor non-responders.
For research and educational use only. Source values are reproduced from the current PeptidesEuro content dataset and are not medical advice.
Quality and specifications
Product details
- Product code
- L-PT141-10
- Availability
- In Stock
- Evidence tier
- Established
- Format
- Lyophilized
- Purity
- 99.3%
- Vial size
- 10mg
Reconstitution reference
- Bacteriostatic water
- 2 mL
- Concentration
- 5mg/mL (5mcg per unit). Standard 1mg dose = 200 units (0.2mL). Starting dose 0.5mg = 100 units.
- Syringe
- 29-31G insulin
Research parameters
- Standard amount
- 1000 µg
- Alternative amount
- 2000 µg
- Vial
- 10 mg
- Dataset estimate
- ~10 doses at 1mg each (1 vial of 10mg). As-needed use, not daily.
Lab report record
- Laboratory
- Janoshik Analytical
- Test date
- 2026-03-01
- Document
- PDF not attached
See the science
-
PMID 12851303
Read study: PT-141: a melanocortin agonist for the treatment of sexual dysfunction (opens in a new tab)
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Dose-dependent increase in erectile activity in healthy men and ED patients. Works through central melanocortin receptors, not peripheral vasodilation.
-
RECONNECT Phase 3 trials — Bremelanotide for HSDD in premenopausal women
Statistically significant improvement in sexual desire and reduction in distress scores in women with HSDD. Basis for FDA approval of Vyleesi in 2019.
-
PT-141 in male erectile dysfunction: efficacy in PDE5 inhibitor non-responders
Effective in men who had failed PDE5 inhibitors (Viagra/Cialis). Works through entirely different CNS pathway — melanocortin vs nitric oxide/PDE5.
Studies are listed for reference. Most were carried out in animal or cell models; their findings do not establish safety or effect in humans.
Further reading
Community evidence
- Source window English Reddit Updated 13 Aug 2026 · 10-year window
- Coverage confidence Low Confidence in the available community sample
- Distribution Pending Not enough data for a distribution.
Selected reports
-
5 years agor/SEXONDRUGS · Post
I really don't like being punctured, so I'll go ahead and say that injecting it is the biggest downside. … At first I felt sick and weak, I was gonna go for a run but instead I laid down for 30 minutes.
Based on 1 qualifying reports from 1 threads. 26 candidates excluded as duplicates, promotion, deleted content, or lacking concrete personal experience. Reddit self-reports are not medical evidence or proof of causation.
Questions about PT-141
Questions and answers recorded for this product.
PT-141 works through the central nervous system (melanocortin receptors in the brain) to increase sexual desire and arousal. Viagra and Cialis work peripherally by increasing blood flow through PDE5 inhibition. PT-141 affects desire, not just mechanics — which is why it works in some people who don't respond to PDE5 inhibitors. It's also one of the few compounds studied for female sexual dysfunction.
PT-141 is used as-needed, not on a daily cycle like most peptides. FDA labeling for Vyleesi recommends no more than 1 dose per 24 hours and no more than 8 doses per month. Most research protocols use 0.5-2mg SC administered 1-4 hours before anticipated activity. Start at the low end (0.5mg) to assess nausea tolerance before increasing.
Nausea is the most commonly reported side effect — approximately 40% of women in clinical trials experienced it. In men, rates are lower but still notable. The nausea is typically transient (30-60 minutes) and dose-dependent. Community tip: start at 0.5mg and increase gradually. Taking it on an empty stomach and staying hydrated may help.
Reviews
There are no reviews for this product yet.
Related products
How ordering works
Product details, references and your order stay connected.
-
Choose the compound
Pick a compound and vial size in the catalogue.
-
Review product information
Open the product details and supporting research.
-
Keep the references
Save the source references for your records.
Why order from PeptidesEuro
Compound profiles
Structure, available sizes and handling notes on one record.
Study references
Product pages link to the studies behind each compound.
One order record
Orders and their details stay in your account.
Clear product data
Price, stock status and tax shown on every product.
PeptidesEuro is a research materials supplier operated by Pepticore LLC. We provide high-purity peptides and research compounds for in-vitro laboratory and scientific research purposes. All products are sold strictly for research use only and are not intended for human or animal consumption.
No. All products sold through meimx.com are intended strictly for in-vitro laboratory and scientific research purposes only. They are not intended for human or animal consumption, injection, ingestion, inhalation, or any form of administration to living organisms. By purchasing from PeptidesEuro, you acknowledge and agree to these terms as outlined in our Terms of Service.
No. Our products have not been evaluated, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. They are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. PeptidesEuro is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
No. PeptidesEuro does not provide medical advice, treatment recommendations, or dosing instructions. Any information on our website, including product descriptions and referenced research, is provided for educational and informational purposes only. If you have medical questions, please consult a licensed healthcare provider.
Research Use Only means that our products are sold exclusively as reference standards and research materials for use in laboratory and scientific research settings. Purchasers agree to use all products solely for legitimate research purposes in compliance with all applicable laws and regulations.
Ready to order PT-141?
Browse the catalogue or answer one question in the product finder.